Keane William F, Lyle Paulette A
US Human Health, Merck & Co., Inc., 351 N. Sumneytown Pike, UG4A-025, North Wales, PA 19454, USA.
Cardiol Clin. 2005 Aug;23(3):363-72. doi: 10.1016/j.ccl.2005.03.004.
Cardiovascular complications are common inpatients with kidney disease. Regulating the lipid levels in these patients is important so that the risks of kidney and cardiovascular complications can be minimized. Lipid regulation decreases the incidence of coronary vascular events and other vascular complications in patients with kidney disease; however, whether lipid regulation slows progression of kidney disease is not yet known. Additional studies of the implications of dyslipidemia in patients with kidney disease are needed.
心血管并发症在肾病患者中很常见。调节这些患者的血脂水平很重要，这样可以将肾脏和心血管并发症的风险降至最低。血脂调节可降低肾病患者冠状动脉血管事件和其他血管并发症的发生率；然而，血脂调节是否能减缓肾病进展尚不清楚。需要对肾病患者血脂异常的影响进行更多研究。
